Other drugs used for MS also target the immune response; of note, teriflunomide, a disease-modifying therapy for MS (He et al., 2012), limits the proliferative responses of B- and T-cells by targeting DNA synthesis, i.e., inhibiting dihydroorotate dehydrogenase (Warnke et al., 2009). Here, DHODH is linked to myeloid sarcoma.